Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($26.12); post-transaction worth based connected Aug. 3, 2026, marketplace adjacent ($25.94).

Key questions

• What was the information down this disposition of shares?
  The merchantability was non-discretionary, executed solely to fulfill taxation withholding requirements associated with the vesting of Restricted Stock Units. This benignant of transaction is regular and does not typically awesome a displacement successful management's sentiment regarding the company's valuation oregon prospects.

• How is the insider's indirect ownership structured?
  The ~233,000 shares held indirectly are distributed crossed aggregate vehicles, including The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, and The Watanabe 2016 Irrevocable Trust, arsenic good arsenic an entity called Watanabe Ventures, LLC. Todd Watanabe disclaims beneficial ownership of these securities but to the grade of his pecuniary interest.

• What is the existent standard of the insider's alignment with the company?
  Despite the caller sale, the insider retains a important involvement successful Arcutis, holding much than 950,000 full shares. This presumption was valued astatine $24.65 cardinal arsenic of the Aug. 3, 2026, marketplace close, and the banal has delivered an 82% instrumentality implicit the 12 months ending connected the transaction date.

• Are determination different stock classes that interaction the ownership profile?
  Arcutis has not reported different stock classes for this insider successful the existent filing. The reported holdings dwell wholly of communal stock, providing a wide presumption of the insider's nonstop and indirect vulnerability to the company's equity performance.

Company Overview

Company Snapshot

• Arcutis Biotherapeutics develops and commercializes innovative topical biopharmaceutical therapies for dermatological conditions, with its flagship merchandise ARQ-151 (roflumilast cream), approved for treating plaque psoriasis and atopic dermatitis, generating the bulk of the company's revenue.

• The institution operates a biopharmaceutical concern exemplary focused connected the development, regulatory approval, and commercialization of proprietary dermatology therapies, leveraging its expertise successful topical formulations and immunomodulatory compounds.

• Arcutis chiefly serves dermatologists and their patients successful the United States, targeting individuals with chronic inflammatory tegument conditions, including psoriasis, atopic dermatitis, and different related dermatological disorders.